Reducing Neuroinflammation via Inhibition of Fibrinogen Deposition and Microglial Activation as an Underlying Mechanism of Paning I Decoction in Ameliorating Parkinson's Disease Symptoms
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867020332633686016 |
|---|---|
| author | Yan‐Jun Chen Jing‐Wen Chen Ming‐Rong Xie Rui‐Zhen Wang Yu‐Ling Wan Jie Zeng Bing‐Wu Zhong Sheng‐Qiang Zhou Fang Liu |
| author_facet | Yan‐Jun Chen Jing‐Wen Chen Ming‐Rong Xie Rui‐Zhen Wang Yu‐Ling Wan Jie Zeng Bing‐Wu Zhong Sheng‐Qiang Zhou Fang Liu Yan‐Jun Chen Jing‐Wen Chen Ming‐Rong Xie Rui‐Zhen Wang Yu‐Ling Wan Jie Zeng Bing‐Wu Zhong Sheng‐Qiang Zhou Fang Liu |
| collection | Wiley Open Access |
| contents | Reducing Neuroinflammation via Inhibition of Fibrinogen Deposition and Microglial Activation as an Underlying Mechanism of Paning I Decoction in Ameliorating Parkinson's Disease Symptoms Yan‐Jun Chen Jing‐Wen Chen Ming‐Rong Xie Rui‐Zhen Wang Yu‐Ling Wan Jie Zeng Bing‐Wu Zhong Sheng‐Qiang Zhou Fang Liu Immunity, Inflammation and Disease ABSTRACT Background Parkinson's disease (PD) is a major neurodegenerative disorder. Some patients show limited response to standard therapies, driving the need for new complementary treatments. Paning I decoction (PNID), a traditional herbal formula, has shown the potential to alleviate PD symptoms, but its exact mechanisms remain unclear. Methods We tested PNID in a mouse model of PD induced by a 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Mice received different PNID doses to evaluate symptom alleviation. We used behavioral tests and laboratory analyses to study brain changes, including neuron damage assessment, dopamine and tyrosine hydroxylase (TH) measurements, blood–brain barrier (BBB) integrity and microglia evaluation, and inflammatory marker analysis. Results PNID treatment alleviated PD symptoms in a dose‐dependent manner. High‐dose PNID performed similarly to Madopar. Neuron protection: increased dopamine and TH expression. BBB repair: less leakage and fibrinogen accumulation. Regulation of polarization: shifted microglia from M1 to M2 states. Inflammation control: lowered pro‐inflammatory factors (IL‐6, IL‐1β, and TNF‐α) while increasing anti‐inflammatory factors (IFN‐β, IL‐10, and IL‐4). Conclusions PNID may serve as a promising complementary therapy for PD. Benefits may come from the repair of the BBB, reduction of fibrinogen deposition, and decline in neuroinflammation by modulating microglial polarization. 10.1002/iid3.70310 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/iid3.70310 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_iid3_70310 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2026 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Reducing Neuroinflammation via Inhibition of Fibrinogen Deposition and Microglial Activation as an Underlying Mechanism of Paning I Decoction in Ameliorating Parkinson's Disease Symptoms Yan‐Jun Chen Jing‐Wen Chen Ming‐Rong Xie Rui‐Zhen Wang Yu‐Ling Wan Jie Zeng Bing‐Wu Zhong Sheng‐Qiang Zhou Fang Liu Immunity, Inflammation and Disease Reducing Neuroinflammation via Inhibition of Fibrinogen Deposition and Microglial Activation as an Underlying Mechanism of Paning I Decoction in Ameliorating Parkinson's Disease Symptoms Yan‐Jun Chen Jing‐Wen Chen Ming‐Rong Xie Rui‐Zhen Wang Yu‐Ling Wan Jie Zeng Bing‐Wu Zhong Sheng‐Qiang Zhou Fang Liu Immunity, Inflammation and Disease ABSTRACT Background Parkinson's disease (PD) is a major neurodegenerative disorder. Some patients show limited response to standard therapies, driving the need for new complementary treatments. Paning I decoction (PNID), a traditional herbal formula, has shown the potential to alleviate PD symptoms, but its exact mechanisms remain unclear. Methods We tested PNID in a mouse model of PD induced by a 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Mice received different PNID doses to evaluate symptom alleviation. We used behavioral tests and laboratory analyses to study brain changes, including neuron damage assessment, dopamine and tyrosine hydroxylase (TH) measurements, blood–brain barrier (BBB) integrity and microglia evaluation, and inflammatory marker analysis. Results PNID treatment alleviated PD symptoms in a dose‐dependent manner. High‐dose PNID performed similarly to Madopar. Neuron protection: increased dopamine and TH expression. BBB repair: less leakage and fibrinogen accumulation. Regulation of polarization: shifted microglia from M1 to M2 states. Inflammation control: lowered pro‐inflammatory factors (IL‐6, IL‐1β, and TNF‐α) while increasing anti‐inflammatory factors (IFN‐β, IL‐10, and IL‐4). Conclusions PNID may serve as a promising complementary therapy for PD. Benefits may come from the repair of the BBB, reduction of fibrinogen deposition, and decline in neuroinflammation by modulating microglial polarization. 10.1002/iid3.70310 http://creativecommons.org/licenses/by/4.0/ |
| title | Reducing Neuroinflammation via Inhibition of Fibrinogen Deposition and Microglial Activation as an Underlying Mechanism of Paning I Decoction in Ameliorating Parkinson's Disease Symptoms |
| topic | Immunity, Inflammation and Disease |
| url | https://onlinelibrary.wiley.com/doi/10.1002/iid3.70310 |